Biogen Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BIIB Nasdaq 2836 www.biogen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biogen Inc.

Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock - Dec 10th, 2024 1:32 pm
Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown - Dec 9th, 2024 6:44 pm
Biogen cut at Jefferies as '2025 has a tough setup' - Dec 9th, 2024 5:27 pm
Is Eli Lilly Stock A Buy After Zepbound Bests Wegovy In A Head-To-Head Study? - Dec 5th, 2024 1:30 pm
"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico - Dec 4th, 2024 11:31 pm
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio - Nov 29th, 2024 2:40 pm
Why Biogen Inc. (BIIB) is One of the Cheapest Stocks to Buy on Robinhood? - Nov 28th, 2024 11:08 am
"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea - Nov 28th, 2024 12:31 am
Why Is Biogen Inc. (BIIB) Among the Worst Performing Healthcare Stocks in 2024? - Nov 27th, 2024 2:15 pm
Goldman Sachs: Biogen Inc. (BIIB) Is A Top Growth Investor Stock - Nov 22nd, 2024 12:45 pm
Biogen price target lowered to $207 from $251 at Mizuho - Nov 22nd, 2024 11:45 am
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside - Nov 20th, 2024 6:32 pm
Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now - Nov 20th, 2024 12:06 am
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity - Nov 19th, 2024 6:00 am
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026 - Nov 18th, 2024 6:18 pm
Needham downgrades Biogen on slow growth of Alzheimer's drug - Nov 18th, 2024 4:30 pm
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ - Nov 18th, 2024 12:00 pm
Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now? - Nov 18th, 2024 9:25 am
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe - Nov 15th, 2024 2:04 pm
European committee takes a second look at Alzheimer's drug and now says it should be approved - Nov 14th, 2024 7:20 pm